Before IP for combo, NCE had more relevance for longer (5yrs) valuation. Now with combo and Anchor patents rolling in 3 yrs NME for December Anchor (Dec 2013,2014,2015) plus sNDA for end of 2014 combo (Dec 2014, 2015, Dec 2016) NCE now for Marine means NOTHING. (2012,2013,2014,2015, July 2016)
I think that Amarin and Elan are like the good old boy's network. I not sure a BO is in order, but a partner ship deal may certainly be good! I enjoyed listening to some of the Elan conference call with the Irish accent's. I think the best sales network would be GSK and maybe a couple of others.
Amrn does not need 1B from elan. Just 100M$ senior unsecured loan at something like 15%, say even 20% to properly staff and launch Anchor and the numbers will speak for themselves.
My wag is that Azn and other BPs have sniffed around amrn and Anchor but knowing the financial situation , they have been lowballing their offers , of which the Omthera BO is an example.
Backing out the 62M$ cash that omth has from their IPO and that the CVR is basically an option, the deal is cheap. It could have been cheaper had their M&A team done their job (I agree with Dew on this) and bought before IPO. That 88% premium is a panic signal imo.
Nevertheless BP is BP. Nice is not their modus operandi.
With the proper financial mean to launch Anchor, amrn is another future lipitor story waiting to happen.
News 
Market Data 
Discover 
AI
